News

Aurobindo Pharma Limited has incorporated a new wholly owned subsidiary, Auropharm Overseas Limited, in India with an initial share capital of Rs 10,00,000 divided into 1,00,000 equity shares of Rs 10 each. The object of the newly incorporated subsidiary is to undertake manufacturing and marketing operations in India and foreign countries, and Aurobindo Pharma stated that the acquisition is a related party transaction.

Net profit of Aurobindo Pharma rose 25.20% to Rs 1032.56 crore in the quarter ended June 2026 as against Rs 824.75 crore during the previous quarter ended June 2025. Sales rose 16.86% to Rs 9105.82 crore in the quarter ended June 2026 as against Rs 7791.77 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales9105.827791.77 17 OPM %20.6420.57 - PBDT2042.091612.50 27 PBT1555.271206.80 29 NP1032.56824.75 25 Powered by Capital Market - Live News

Aurobindo Pharma announced that the Annual General Meeting(AGM) of the company will be held on 27 August 2026.

Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 5 August 2026.

Aurobindo Pharma announced that PT Aurogen Pharma Indonesia, a wholly owned stepdown subsidiary of the Company, has incorporated a new wholly owned subsidiary company by the name of PT Auro Pharm Indonesia, in Indonesia.The object of incorporation of this wholly owned step down subsidiary is to undertake manufacturing operations in Indonesia.